Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK of Oral PTH (RT-102) in Healthy Women
NCT05164614Phase 1Completed
- Sponsor
- Rani Therapeutics
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of teriparatide in osteoporosis (5 arms), sponsored by Rani Therapeutics. Primary endpoints: Maximum Plasma Concentration at 24 hours, Time to Maximum Plasma Concentration at 24 hours and 1 more. Started Feb 2022; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05164614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164614.